HIF1A and breast carcinoma: AT-533, a novel Hsp90 inhibitor, is considered a potential candidate for breast cancer treatment, as it inhibits breast cancer growth and angiogenesis by blocking HIF-1α/VEGF/VEGFR-2 signaling pathway (107).